The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 2
- 2 renewals
- Median first-year cost
- $1,853,377
- $3,706,754 in all
- Institutions
- 2
- 2 contact PIs
Awards by fiscal year
0
0
0
0
0
0
0
0
0
0
0
2
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- MYOSIN THERAPEUTICS INC.1
- STINGRAY THERAPEUTICS, INC.1
Most frequent study sections
- Special Emphasis Panel (ZCA1 TCRB-Q (J1))2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2025 | Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas2R44CA278293-04 | Brownstein, Michael J | MYOSIN THERAPEUTICS INC., FL | First-year cost $2,245,802 | Study section ZCA1 |
| FY2025 | A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab2R44CA278144-03 | Kaadige, Mohan RaoShah, MonilSharma, Sunil | STINGRAY THERAPEUTICS, INC., TX | First-year cost $1,460,952 | Study section ZCA1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-15-0.3.4. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.